Virpax Pharmaceuticals (VRPX) Announces 1:25 Reverse Share Split Mar 19, 2025 08:00AM
Virpax Pharmaceuticals Announces Reverse Stock Split Mar 19, 2025 08:00AM
Virpax Pharmaceuticals (VRPX) Receives Positive Probudur Results for Dose Range Study Moves Towards Next Steps in IND Mar 18, 2025 04:01PM
Virpax Receives Positive Probudur™ Results for Dose Range Study Moves Towards Next Steps in IND Mar 18, 2025 04:01PM
Virpax Looking to Use MET to Develop Intranasal COVID Vaccine Mar 7, 2025 08:00AM
View Older Stories

Mar 5, 2025 04:01PM Virpax’s NES100 to be Presented at The Society of Toxicology by NCATS
Feb 27, 2025 04:01PM Virpax Pharmaceuticals (VRPX) Reports Positive Results in Human Study for its Molecular Envelope Technology
Feb 27, 2025 04:01PM Virpax Reports Positive Results in Human Study for its Molecular Envelope Technology
Feb 13, 2025 04:01PM Virpax Pharmaceuticals (VRPX) Confirms Positive Results with US Army with Probudur for Combat Care Study
Feb 13, 2025 04:01PM Virpax Confirms Positive Results with US Army with Probudur™ for Combat Care Study
Jan 31, 2025 08:30AM Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials Conference
Nov 22, 2024 08:31AM Virpax Pharmaceuticals (VRPX) Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur
Nov 22, 2024 08:30AM Virpax Announces Positive Results for the Swine Model Dose Range Finding Study for Probudur™
Nov 21, 2024 04:07PM Virpax Pharmaceuticals (VRPX) Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alt
Nov 21, 2024 04:05PM Virpax Announces Agreement with the U.S. Department of Health and Human Services for the Developmental Extension for NES100 Towards IND for Acute and Chronic Non-Cancer Pain Alternative
Aug 13, 2024 07:30AM Virpax Pharmaceuticals Reports 2024 Second Quarter Results and Recent Developments
Aug 8, 2024 07:30AM Virpax Pharmaceuticals to Present at Sidoti Virtual Investor Conference August 14-15
Jul 24, 2024 07:30AM Virpax Pharmaceuticals (VRPX) Regains Nasdaq Compliance
Jul 24, 2024 07:30AM Virpax Regains Compliance with Nasdaq Minimum Bid Price
Jul 10, 2024 07:30AM Virpax Pharmaceuticals (VRPX) Positive Results of Swine Model Pilot Study for Probudur
Jul 10, 2024 07:30AM Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™
Jul 8, 2024 07:30AM Virpax Pharmaceuticals Secures $2.5 Million Loan Financing and an Agreement with an Institutional Investor to Negotiate Additional Funding
May 29, 2024 07:30AM Virpax® Pharmaceuticals to Present at 2024 BIO International Convention
May 15, 2024 08:00AM Virpax Pharmaceuticals (VRPX) Prices 1.67M Share Offering at $1.35/sh
May 15, 2024 08:00AM Virpax Announces Pricing of $2.25 Million Public Offering
May 13, 2024 04:10PM Virpax Pharmaceuticals Reports 2024 First Quarter Results and Recent Developments
Apr 30, 2024 07:31AM Virpax Pharmaceuticals (VRPX) Announces Results of Maximum Tolerated Dose Study for Probudur
Apr 30, 2024 07:30AM Virpax Announces Results of Maximum Tolerated Dose Study for Probudur™
Mar 26, 2024 07:30AM Virpax Pharmaceuticals Reports 2023 Year-End Results
Feb 27, 2024 07:31AM Virpax Pharmaceuticals (VRPX) Announces 1:10 Reverse Share Split
Feb 27, 2024 07:31AM Virpax Pharmaceuticals Announces Reverse Stock Split to Regain Compliance with Nasdaq’s Minimum Bid Price
Feb 27, 2024 07:30AM Virpax Pharmaceuticals Announces Proposed Settlement of Litigation with Sorrento Therapeutics, Inc. and Scilex Pharmaceuticals, Inc.
Feb 7, 2024 07:31AM Virpax Pharmaceuticals (VRPX) Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
Feb 7, 2024 07:30AM Virpax Pharmaceuticals Announces Preliminary Results of ProbudurTM Pilot Study with the U.S. Army Institute of Surgical Research
Dec 29, 2023 07:30AM Virpax Pharmaceuticals Announces Results of Special Shareholders Meeting
Nov 17, 2023 07:12AM Virpax Pharmaceuticals (VRPX) Receives Nasdaq Notice Related to Delayed Form 10-Q Filing
Nov 17, 2023 07:10AM Virpax Pharmaceuticals Announces Notification from Nasdaq Related to Delayed Form 10-Q Filing
Nov 17, 2023 07:02AM Virpax Pharmaceuticals (VRPX) accepts resignation of Anthony P. Mack as CEO and Chairman
Nov 17, 2023 07:00AM  Virpax Pharmaceuticals Announces Leadership Transition
Nov 15, 2023 04:15PM Virpax Pharmaceuticals Reports 2023 Third Quarter Results and Recent Developments
Oct 31, 2023 08:58AM Virpax Pharmaceuticals (VRPX) Announces that Envelta Remains on Track for Trial in Humans Following FDA Review
Oct 31, 2023 08:58AM Virpax Pharmaceuticals Announces that Envelta™ Remains on Track for Trial in Humans Following FDA Review
Oct 12, 2023 08:03AM Virpax Pharmaceuticals (VRPX) Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
Oct 12, 2023 08:02AM Virpax Pharmaceuticals Announces Extension of CRADA with the U.S. Army Institute of Surgical Research
Oct 2, 2023 08:58AM Gerald W. Bruce Appointed President and CEO of Novvae™ Pharmaceuticals
Sep 27, 2023 08:58AM Virpax Pharmaceuticals (VRPX) Reports Results of Probudur Dose Escalation Studies
Sep 27, 2023 08:58AM Virpax Pharmaceuticals Announces Results of Probudur™ Dose Escalation Studies
Sep 26, 2023 08:58AM Virpax Pharmaceuticals to Present at the LD Micro Main Event XVI
Sep 21, 2023 10:00AM Altasciences Chosen by Virpax to Support the Development of a New Drug to Prevent Spread of Flu-like Viruses
Sep 18, 2023 07:58AM Virpax Pharmaceuticals (VRPX) Announces Formation of Novvae Pharmaceuticals
Sep 18, 2023 07:58AM Virpax Pharmaceuticals Announces the Formation of Novvae™ Pharmaceuticals
Sep 5, 2023 09:00AM Virpax Pharmaceuticals (VRPX) Pharmaceuticals Updates on Litigation
Sep 5, 2023 09:00AM Virpax Pharmaceuticals Updates on Litigation
Aug 28, 2023 08:58AM Virpax® Pharmaceuticals to Present at H.C. Wainwright 25th Annual Global Investment Conference
Aug 14, 2023 09:00AM Virpax Pharmaceuticals Reports 2023 Second Quarter Results and Recent Developments
View Older Stories